¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"outer zone of renal medulla"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • renal atrophy
    ½ÅÀ§Ãà(ãìê×õê)
  • renal atrophy
    ½ÅÀ§Ãà
  • renal autonomic plexus
    ½Å ÀÚÀ²½Å°æÃÑ
  • renal autotransplantation
    ½Å ÀÚ°¡À̽Ä
  • renal azotemia
    ½Å¼º °íÁú¼ÒÇ÷Áõ
  • renal ballottement
    ½ÅºÎ±¸°¨(ãìݩϹÊï).
  • renal ballottement
    ½ÅºÎ±¸°¨(ãìݩϹÊï)
  • renal bench surgery
    ü¿Ü½Å¼ö¼ú
  • renal biopsy
    ½Å»ý°Ë(ãìßæËþ).
  • renal bleeding
    ½ÅÃâÇ÷(ãìõóúì).
  • renal bleeding
    ½ÅÃâÇ÷(ãìõóúì)
  • renal blockade
    ½ÅÂ÷´Ü(ãìó´Ó¨).
  • renal blood flow
    ½ÅÇ÷·ù·®
  • renal blood flow =RBF
    ½ÅÇ÷·ù(·®)(ãìúìêüåÖ).
  • renal blood vessel
    ÄáÆÏÇ÷°ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • coronal zone
    Ä¡°ü´ë(öÍήÓá).
  • critical zone
    À§Çè´ë(ËôÌ´ËÀ), ÇѰè´ë(̰˭ËÀ).
  • dead zone
    »ç°¢ Áö´ë
  • dentiongenic zone
    »ó¾ÆÀüÁú(ßÚä³îñòõ).
  • differentiation zone
    ºÐÈ­±¸¿ª
  • discharge zone
    ¹æÀü¹üÀ§(Û¯ï³ÛôêÌ)
  • dolorogenic zone
    µ¿Åë¹ß»ý´ë.
  • dolorogenic zone
    µ¿Åë¹ß»ý´ë(ÔÙ÷ÔÛ¡ßæÓá).
  • dysacoustic zone
    ÀÌÀ½Çâ±Ç
  • ependymal zone
    »óÀÇ´ë(ß¾ëýÓá).
  • epileptogenic zone
    °£Áú¹ß»ý´ë.
  • equivalence zone
    ´ç·®±¸¿ª.
  • erogenic zone
    ¼º°¨´ë
  • erogenic zone
    ¼º°¨Á¶¼º´ë(àõÊïðãà÷Óá), »öÁ¤´ë(ßäï×Óá)
  • excess zone, antibody
    Ç×ü°úÀ׿ª (Ç׿øÇ×ü¹ÝÀÀÀÇ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
AVZ avascular zone
BMZ basement membrane zone
CDZ chlordiazepoxide; conduction delay zone
CFZ capillary free zone
CTZ chemoreceptor trigger zone; chlorothiazide
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
OAM outer acrosomal membrane
% OD outer diameter
OE outer envelope
OMCDi outer medullary collecting duct
omp1 outer membrane protein gene
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • renal cyst puncture
    ½Å ³¶Á¾ õÀÚ
  • renal damage
    ½Å Àå¾Ö
  • renal depressor system
    ½Å °­¾Ð°è
  • renal disease
    ½Å Áúȯ
  • renal dissociation jaundice
    ½Å ÇØ¸®¼º Ȳ´Þ
  • renal duct
    ½Å°ü
  • renal dysfunction
    ½Å ±â´É Àå¾Ö
  • renal dysplasia
    ½Å ÀÌÇü¼º, ½Å ÀÌÇü¼ºÁõ
  • renal ectopia
    ½Å ÀüÀ§, À̼Ҽº ½Å
  • renal failure
    ½Å ºÎÀü
  • renal fascia
    ÄáÆÏ ±Ù¸·
  • renal fossa
    ½ÅÀå ¿À¸ñ, ½Å¿Í
  • renal function test
    ½Å ±â´É °Ë»ç, ½Å ±â´É ½ÃÇè
  • renal glomeruli
    ½Å »ç±¸Ã¼
  • renal gout
    ½Å¼º Åëdz
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
latent zone That portion of the cerebral cortex, the stimulation of which produces no movement and a lesion of which produces no symptoms; mainly the more anterior areas of the frontal lobes.
(05 Mar 2000)
frontal zone contraction theory Model proposed to account for the movement of giant amoebae in which cytoplasmic contraction at the front of the leading pseudopod (fountain zone) pulls viscoelastic cytoplasm forward in the centre of the cell and forms a tube of more rigid cytoplasm immediately below the plasma membrane behind the active region. The peripheral contracted cytoplasm relaxes into a weaker gel at the rear and is pulled forward in its turn. Contrasts with the ectoplasmic tube contraction model.
(18 Nov 1997)
Lissauer's marginal zone A longitudinal bundle of thin, unmyelinated and poorly myelinated fibres capping the apex of the posterior horn of the spinal gray matter, composed of posterior root fibres and short association fibres that interconnect neighboring segments of the posterior horn.
Synonym: fasciculus dorsolateralis, tractus dorsolateralis, dorsolateral tract, fasciculus marginalis, Lissauer's bundle, Lissauer's column, Lissauer's fasciculus, Lissauer's marginal zone, Lissauer's tract, marginal fasciculus, Spitzka's marginal tract, Spitzka's marginal zone, Waldeyer's tract, Waldeyer's zonal layer.
(05 Mar 2000)
acute renal failure <nephrology> A sudden decline in renal function may be triggered by a number of acute disease processes.
Examples include sepsis (infection), shock, trauma, kidney stones, kidney infection, drug toxicity (aspirin or lithium), poisons or toxins (drug abuse) or after injection with an iodinated contrast dye (adverse effect).
Chronic renal failure represents a slow decline in kidney function over time. Chronic renal failure may be caused by a number of disorders which include long-standing hypertension, diabetes, congestive heart failure, lupus or sickle cell anaemia. Both forms of renal failure result in a life-threatening metabolic derangement.
(27 Sep 1997)
aminoaciduria, renal Impairment of renal tubular transport of amino acids.
(12 Dec 1998)
back-pressure renal atrophy <radiology> Caliectasis without obstruction, due to repeated episodes of obstruction, gradual loss of renal pyramids
(12 Dec 1998)
base of renal pyramid The outer broad part of a renal pyramid that lies next to the cortex.
Synonym: basis pyramidis renis.
(05 Mar 2000)
branchio-oto-renal syndrome <syndrome> An autosomal dominant disorder manifested by various combinations of preauricular pits, branchial fistulae or cysts, lacrimal duct stenosis, hearing loss, structural defects of the outer, middle, or inner ear, and renal dysplasia. Associated defects include asthenic habitus, long narrow facies, constricted palate, deep overbite, and myopia. Hearing loss may be due to mondini type cochlear defect and stapes fixation.
(12 Dec 1998)
capsular branches of renal artery <anatomy, artery> Branches arising from the renal artery outside of the kidney that are distributed to the renal capsule.
Synonym: rami capsulares arteriae renalis.
(05 Mar 2000)
captopril renal scan <radiology> In a kidney with a lesion in the afferent arteriole (e.g. Atherosclerotic plaque), reflex constriction of the efferent arteriole occurs through angiotensin system thus maintaining renal perfusion. ACE inhibition prevents constriction of efferent arteriole. Therefore, perfusion is decreased to a kidney with afferent lesions and the renal scan to looks WORSE. Bottom line: renal scans appear WORSE with captopril administration if there is a lesion in the afferent arteriole. See: renal artery stenosis
(12 Dec 1998)
carcinoma, renal cell Carcinoma of the renal parenchyma usually occurring in middle age or later and composed of tubular cells in varying arrangements. It was first described in 1826. Possible causal factors are environmental, hormonal, cellular, and genetic. Smoking is a definite risk factor and obesity is associated with increased risk. Renal cell carcinoma accounts for approximately 3% of adult cancer; the male-female ratio is 2:1. It is more common among urban residents than rural.
(12 Dec 1998)
renal <anatomy> Pertaining to the kidney, nephric.
(18 Nov 1997)
renal adenocarcinoma <radiology> Hypernephroma, renal cell carcinoma, arises from proximal collecting tubule, 10% bilateral adenocarcinoma types: papillary, alveolar, onchocytoma vascularity, 85% hypervascular (require pre-op embolization), 10% hypovascular (usually papillary type), 5% avascular associated with: tuberous sclerosis, von Hippel-Lindau syndrome see also: staging
(12 Dec 1998)
renal adenocarcinoma: staging <radiology> Typical presentation: Haematuria . . . . . 70% Fever . . . . . . . 16% Pain . . . . . . . . 50% Polycythemia . . . . 3% Palpable mass . . . 20% Anatomic staging (TNM): T1 Small tumour, kidney not enlarged T2 Large tumour, contained within renal capsule T3 Extension into perinephric fat or renal vein T4 Invasion of adjacent organs
(12 Dec 1998)
renal adenocarcinoma: vascularity <radiology> 85% hypervascular (require pre-op embolization), 10% hypovascular (usually the papillary type), 5% avascular also: 10% are bilateral
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á